OVOksana Ya. Vasiltseva

Oksana Ya. Vasiltseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oksana Ya. Vasiltseva has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • О. Я. Васильцева

    Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина Министерства здравоохранения Российской Федерации (НМИЦ им. ак. Е.Н. Мешалкина Минздрава России)

    13 shared publications
  • Alexander Mikhailovich Chernyavskii

    National Medical Research Center named after Academician E.N. Meshalkin; Novosibirsk State Medical University

    12 shared publications
  • Alexander G. Edemskiy

    Meshalkin National Medical Research Center

    10 shared publications
  • Denis S. Grankin

    Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации, Новосибирск

    8 shared publications
  • I. N. Vorozhtsova

    Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук; Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации

    6 shared publications
  • Rostislav S. Karpov

    Tomsk National Research Medical Center

    6 shared publications

Latest Publications

  • Open Access

    Predictors of the development of residual pulmonary hypertension in patients with chronic thromboembolic pulmonary hypertension

    by Oksana Ya. Vasiltseva, Devran F. Zeinalov, Alexander G. Edemskiy, Алексей Геннадьевич Лавров, Денис Сергеевич Гранкин, Дмитрий Андреевич Сирота, Aleksandr M. Chernyavskiy

    Introduction. After pulmonary endarterectomy (PEA), a third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) develop residual pulmonary hypertension (PH) in the postoperative period, which plays a decisive role in the formation of long-term mortality, but in modern clinical practice there are no tools for predicting its probability. Objective. of the study was to determine predictors of residual pulmonary hypertension after pulmonary endarterectomy. Methods. The retrospective cohort observational study included 353 patients aged 19 to 77 years with CTEPH who underwent PEA at the Federal State Budgetary Institution "National Medical Research Center named after Academician E.N. Meshalkin" from 2004 to 2019. The patients underwent clinical and instrumental examination before PEA, after PEA during the hospital period and in the late period (12 months) after PEA. An analysis of the obtained factors was carried out, non-modifiable and modifiable predictors of residual PH were determined. Results. According to the regression analysis, independent non-modifiable predictors of residual PH after PEA were identified: history of cancer; blood group AB (IV); reperfusion syndrome after PEA; pulmonary vascular resistance >1000 dyn×s×cm–5 according to pulmonary circulation tensiometry data before PEA; the ratio of the systolic excursion of the tricuspid valve annulus to the systolic pressure in the pulmonary artery 50 mmHg after PEA, measured by transthoracic echocardiography during the hospital period; thrombus calcification in the biopsy material of thrombotic masses. In addition, modifiable predictors were identified - delay in diagnosis and treatment of 6 months or more; obesity; smoking; anemia; irregular warfarin intake; failure to achieve target INR values; thrombosis of veins of any localization after LEE in dynamics. Conclusion. For the first time in Russia, modifiable and non-modifiable predictors of residual PH after PEA in patients with CTEPH were identified. An optimization algorithm for early diagnosis and treatment of CTEPH was proposed.

  • Open Access

    Expert consensus on approaches to risk stratification and choice of therapy in patients with inoperable and residual chronic thromboembolic pulmonary hypertension

    by I E Chazova, T V Martynyuk, S N Avdeev, Z S Valieva, O Y Vasiltseva, T N Veselova, V V Gramovich, D S Grankin, N M Danilov, A G Edemskiy, et al.

    On December 13, 2024, the final working group meeting was held, the purpose of which was to discuss the common position of experts on the problem of chronic thromboembolic pulmonary hypertension of various specialties: cardiologists, cardiac surgeons, pulmonologists, on issues of assessing the operability of patients, risk stratification and choice of therapy in patients with inoperable and residual forms of pathology. The discussion field included a wide range of issues that often arise in real clinical practice, but specific answers to them are not given in national and foreign guidelines. On November 8, 2024, at the preparatory stage, 16 experts under the leadership of Academician of the Russian Academy of Sciences I.E. Chazova (chairman) formulated questions for the preparation of a consensus document (without discussion), consistently discussing the feasibility of including each issue in the document and distributing tasks for the final session. Then, at the intermediate stage, experts searched and systematized scientific information on the formulated questions in the PubMed and eLIBRARY systems to prepare sections of the document in accordance with the established tasks. When finalizing the document, experts answered 28 questions: during anonymous voting an individual score was determined for each block from 1 – completely disagree, to 5 – completely agree. It was considered that a strong consensus was achieved with a mean score of M±m 2.5±2, and with a mean score below 2.5, consensus was not achieved. A strong consensus was reached on all issues.


  • Open Access

    Reserve capabilities of the cardiovascular and respiratory systems in patients with chronic thromboembolic pulmonary hypertension

    by O. Ya. Vasiltseva, D. F. Zeynalov, A. G. Edemsky, D. S. Grankin, A. G. Lavrov, D. A. Sirota, A. M. Chernyavskiy, О. Я. Васильцева

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious disease associated with thrombotic lesions of the pulmonary arteries and secondary microvasculopathy, leading to the progression of pulmonary hypertension and heart failure. Pulmonary endarterectomy (PEA) is the preferred treatment for CTEPH.Aim: To study the reserve capabilities of the cardiovascular and respiratory systems in patients with CTEPH.Material and Methods. The retrospective cohort observational study included 403 patients aged 19 to 77 years with CTEPH who underwent PEA at the National Medical Research Center named after. ak. E.N. Meshalkin from 2004 to 2021. Parameters of transthoracic echocardiography, pulmonary circulation tensiometry, pulmonary function tests, six-minute walk test and Borg scale were assessed before surgery, after PEA before discharge and after surgery 12 months later.Results. When comparing transthoracic echocardiography data at the hospital stage after PEA, a decrease in right ventricular systolic pressure was revealed from 82.2 ± 23.1 to 44.9 ± 16.2 mm Hg, leading to an improvement in intracardiac hemodynamics, characterizing the right heart function. These improvements continued into the long-term follow-up. Analysis of pulmonary circulation tensiometry in CTEPH patients after PEA showed that all patients had a significant decrease in mean pulmonary artery pressure from 48.3 ± 14.5 to 27.1 ± 10.7 mmHg (by 1.8 times), which was accompanied by a decrease in pulmonary vascular resistance by 2.8 times and an increase in cardiac output. In the long-term follow-up improvements in the pulmonary circulation tensiometry indicators also persisted. When comparing the indicators of pulmonary function tests, a statistically significant decrease in tidal and minute respiratory volumes was revealed. After PEA six-minute walk test distance increased by 19.0 meters, in the long-term follow-up by 60.6 meters; shortness of breath according to the Borg scale decreased from “severe” to “moderate”, in the long-term follow-up to “mild”.Conclusion. The results obtained demonstrate the continuation of the cardiovascular and respiratory systems recovery processes in the immediate postoperative period, and further during the year of observation after PEA, indicate significant reserve capabilities of the cardiovascular and respiratory systems, and the potential cure of patients with CTEPH.

  • Open Access

    Pharmacological test with nitroglycerin in combination with perfusion SPECT with 99mTc-Technetril in assessing the viability of ischemic myocardium in patients after acute infarction

    by S. M. Minin, O. Ya. Vasiltseva, I. L. Bukhovets, Z. Zh. Anashbaev, Yu. B. Lishmanov, E. A. Ivanovskaya, V. Yu. Ussov, A. M. Cherniavskii, О. Я. Васильцева, В. Ю. Усов

    Aim. To evaluate the possibility of using nitroglycerin sublingually in combination with 99mTc-Technetril cardiac perfusion single-photon emission computed tomography (SPECT) as a test for detecting viable myocardium. Material and methods. 28 male patients with coronary heart disease (CHD) and postinfarction cardiosclerosis were examined. Group 1 included 10 patients with CHD without signs of acute myocardial infarction (AMI). Group 2 comprised 18 patients with CHD, postinfarction cardiosclerosis (PICS). The control group consisted of patients who were subsequently rejected a diagnosis of CHD. Patients took 2 tablets (1 mg) of nitroglycerin sublingually, and then, at the peak of the drug’s action (after 3–5 minutes), they were intravenously administered 370 MBq of 99mTc-Technetril (by Diamed, Russia). Myocardial SPECT with 99mTc-Technetril was performed 1 hour after RFP injection. The next day, myocardial SPECT with 99mTc-Technetril was repeated at rest. Results. When taking tableted nitroglycerin at a dose of 1 mg sublingually, its maximum plasma concentration is on average 0.26 ± 0.04 microcgram/l. It is reached by 110–150 s, then maintained within 10 % of the maximum for 7-9 minutes. Nitroglycerin leads to improvement in global and local contractility and increased LV pumping function in CHD patients. This is most pronounced in individuals with a higher class of angina pectoris after AMI and major changes in intracardiac hemodynamics initially. The nitroglycerin test in combination with 99mTc-Technetril SPECT-CT allowed to identify myocardial areas with improved blood flow and increased EFLV after CABG. Conclusion. The nitroglycerin test in combination with 99mTc-Technetril SPECT-CT is effective for detecting viable myocardium in patients with coronary atherosclerosis and CHD, safe and relatively simple due to the sublingual route of nitroglycerin intake.

  • Open Access

    Therapies of chronic thromboembolic pulmonary hypertension: A review

    by Oksana Vasiltseva, Alexander Edemskiy, Devran Zeinalov, Elena Kliver, Wladimir Ussov, Denis Grankin, Dmitry Sirota, Aleksandr Chernyavskiy

    The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.


  • Open Access

    Chronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, treatment — current state of the problem

    by Alexander M. Chernyavskiy, Alexander G. Edemskiy, Oksana Y. Vasiltseva, Elena N. Kliver, Denis S. Grankin, Dmitriy A. Sirota, Alexander B. Romanov, Чернявский Александр Михайлович, Едемский Александр Геннадьевич

    Chronic thromboembolic pulmonary hypertension is group IV of pulmonary hypertension, which develops with occlusive-stenotic lesions of the pulmonary artery after a pulmonary embolism. There are no clear data on the epidemiology of this disease. At the same time, it is obvious that it is much more widespread than is commonly believed. This is due to the nonspecific clinical picture and the lack of awareness of clinicians about this disease. On the one hand, the pathogenesis of CTEPH is well studied and in many respects similar to pulmonary arterial hypertension, on the other hand, it is not clear why blood clots do not dissolve in a certain percentage of patients. Diagnosis of chronic thromboembolic pulmonary hypertension is fairly well described and should be carried out according to a special algorithm. The treatment of choice is pulmonary endarterectomy. In inoperable patients and patients with residual pulmonary hypertension after surgery, it is possible to perform balloon angioplasty of the pulmonary artery and PAH-specific therapy. In our study, the safety and efficacy of a new method for the treatment of a residual form of chronic thromboembolic pulmonary hypertension, radiofrequency denervation of the pulmonary artery, has been proven. The pathogenetic basis of this technique is the desympathization of the pulmonary circulation by radiofrequency destruction of the autonomic ganglia of the bifurcation of the pulmonary artery and the interruption of the so-called pulmo-pulmonary reflex.


  • Open Access

    Treatment of patients with chronic thromboembolic pulmonary hypertension

    by O. Ya. Vasiltseva, A. E. Uranov, A. G. Edemskiy, E. N. Kliver, D. S. Grankin, D. A. Sirota, A. B. Romanov, A. M. Chernyavskiy, О. Я. Васильцева

    The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.

  • Open Access

    Stenosis of the trunk of the left coronary artery in idiopathic pulmonary hypertension. Case report

    by Sergei N. Ivanov, Alexander G. Edemskiy, Oksana Ya. Vasiltseva, Aleksandr M. Chernyavskiy, Maria V. Kalashnikova, Svetlana V. Seletskaya, Едемский Александр Геннадьевич

    The manuscript presents a clinical case of treatment of a patient with idiopathic pulmonary hypertension and a rare complication left main coronary artery stenosis caused due to compression by the dilated pulmonary artery. This complication was clinically manifested by chest pain. The patient underwent percutaneous coronary angioplasty with stenting of the left main coronary artery and subsequent prescription of combined PAH-specific therapy. During the late follow-up examination in addition to clinical improvement and the absence of pain, 6-minute walking test distance increase, positive dynamics of echocardiography, right heart catheterization, as well as the laboratory marker of heart failure NT-proBNP were noted.


  • Features of pulmonary thromboembolism in women

    by O. Ya. Vasiltseva, K. N. Vitt, A. M. Cherniavsky

    Pulmonary artery embolism (PAE) is usually a diagnosis of exclusion. Verification of a more common pathology takes time, which may become critical for treatment of pulmonary embolism and saving the patient’s life. Since PAE is an acute disease, the time window for medical care largely determines the prognosis. Therefore, the differential diagnostic process should include thromboembolism already at the first visit. It is important to determine risk factors for PAE taking into account the patient’s personality and gender. Obtained data may help the physician to determine quickly the expedience of visualizing studies, such as ventilation/perfusion scintigraphy, angiopulmonography, computed tomographic angiopulmonography. For women, it is important to collect specific information, such as the presence of large uterine fibroids, use of combined oral contraceptives or hormonal replacement therapy; to ask how long ago the patient had pregnancy and delivery, whether she has thrombophilia or oncological diseases.


  • Open Access

    Chronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus

    by E. N. Kliver, O. Vasiltseva, A. G. Edemskiy, D. S. Grankin, D. F. Zeinalov, A. M. Cherniavsky, О. Я. Васильцева

    Metabolic disorders represent a serious medical and social problem and are risk factors for the development of thromboembolic complications. Disturbances of both carbohydrate and fat metabolism contribute to an increase in blood viscosity, creating prothrombotic conditions, which are not always objectively assessed even by specialists. In addition, multiple comorbid conditions usually significantly complicate the prognosis. The article presents a clinical case of recurrent thrombosis of the right atrium and the orifices of the superior and inferior vena cava in a 39-year-old patient with type 2 diabetes mellitus, obesity, arterial hypertension, and varicose vein disease.